A cost-effectiveness analysis of Herceptin® (trastuzumab) in combination with Paclitaxel as a first line treatment for HER2 positive (3+) Metastatic Breast Cancer (MBC) patients in the UK
A. Hall Ratcliffe, C. J. Poole, David Miles
European Journal of Cancer, 2001
Abstract
An abstract is not available for this record. Please visit the publisher website for more details.